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The quaternary neutralizing epitope (QNE) of HIV-1
gp120 ispreferentially expressedon the trimericenve-
lope spikes of intact HIV virions, and QNE-specific
monoclonal antibodies (mAbs) potently neutralize
HIV-1. Here, we present the crystal structures of the
Fabs of human mAb 2909 and macaque mAb 2.5B.
Both mAbs have long beta hairpin CDR H3 regions
>20 A˚ in length that are each situated at the center of
their respective antigen-binding sites. Computational
analysis showed that the paratopes include thewhole
CDR H3, while additional CDR residues form shallow
binding pockets. Structural modeling suggests a
way to understand the configuration of QNEs and
the antigen-antibody interaction for QNE mAbs. Our
data will be useful in designing immunogens that
may elicit potent neutralizing QNE Abs.
INTRODUCTION
Many monoclonal antibodies (mAbs) specific for the envelope
(Env) glycoproteins of HIV-1 have been isolated that are able to
neutralize virus infectivity. Yet none has displayed neutralization
potencies comparable to the subnanogram neutralizing activity
of a recently identified family of mAbs isolated from HIV-infected
humans and SHIV-infected macaques (Gorny et al., 2005;
Walker et al., 2009; Robinson et al., 2010). These mAbs have
all been selected with neutralization assays, and each targets
an epitope selectively displayed on the surface of intact virus
particles and infected cells. They react weakly, or not at all,
with monomeric forms of gp120, and appear to react preferen-
tially with the gp120 trimeric form of the mature Env spike;
consequently, these mAbs are thought to react with a complex
region on the Env spike referred to as the ‘‘quaternary neutral-
izing epitope’’ (QNE) (Gorny et al., 2005).
Antibodies to the QNE were first suggested to be present in
SHIV89.6P-infected macaques. Though difficult to characterizeStructure 19,in polyclonal sera, their activity appeared to map to a discontin-
uous epitope formed by the second and third variable regions
(V2 and V3) on the virus’s trimeric Env spikes (Etemad-Mogha-
dam et al., 1998). Similar Abs mapping to variable regions in
gp120 were described in an HIV-infected chimpanzee (Cho
et al., 2000; Chen et al., 2001). Polyclonal Abs from these animals
displayed extreme neutralizing potency for the viruses infecting
the donors. The first QNE-specific human mAb, 2909, was iso-
lated from peripheral blood cells of a clade B HIV-infected
long-term nonprogressor on the basis of its potent neutralization
of HIVSF162; the epitope of this mAb was mapped to portions of
the V2 and V3 regions of gp120 (Gorny et al., 2005). While target-
ing several residues in V2 and V3, the narrow neutralizing
capacity of mAb 2909 for HIVSF162 maps primarily to a single
residue in V2 at residue 160 (HXB2 numbering (Ratner et al.,
1987)) where the common glycosylated asparagine is replaced
by lysine, an unusual substitution at this position (Honnen
et al., 2007). After the description of mAb 2909, two clonally
related broadly neutralizing human mAbs, PG9 and PG16,
were isolated from a single clade A-infected volunteer on the
basis of their ability to neutralize HIVJR-CSF; again, their epitopes
were mapped to regions in V2 and V3, but the reactivity of these
mAbs was much broader (Walker et al., 2009). More recently,
several macaqueQNEmAbswere isolated from threemacaques
infected with SHIVSF162P4 (Robinson et al., 2010). These mAbs
again target the QNE composed of V2 and V3; they are narrow
in their neutralizing activity and display a variety of patterns
responsible for epitope-mAb interaction.
A common factor of these QNE-specific mAbs is their recog-
nition of both V2 and V3 regions, which are highly variable
portions of gp120 known to play critical roles in epitope masking
and coreceptor binding, respectively. Each QNE-specific mAb
appears to target a unique but related antigenic determinant
(epitope), and as such, thesemAbs are likely to belong to a single
family (Walker et al., 2010). There are other Ab families found to
have reactivity to distinct but overlapping epitopes, such as the
class of anti-V3 mAbs and the mAbs specific for cluster I and for
cluster II of gp41 (Xu et al., 1991; Jiang et al., 2010).
Due to the dependence of the QNE on the formation of gp120
trimer, crystallization of the antigen-antibody complexes of
QNE mAbs is extremely challenging, if not impossible, with the691–699, May 11, 2011 ª2011 Elsevier Ltd All rights reserved 691
Table 1. Crystallographic Data Collection and Refinement
Statistics
Fab 2909 Fab 2.5B
Data Collection
Space group P3221 P21
Cell dimensions
a, b, c (A˚) 178.50, 178.50,
218.90
77.83, 72.82,
88.90
a, b, g () 90.0, 90.0, 120.0 90.0, 115.64, 90.0
Resolution (A˚) 46.6–3.2
(3.31–3.2)
29.7–1.9
(1.97–1.90)
Rmerge 0.129 (0.695) 0.085 (0.599)
I/sI 15.5 (1.8) 17.9 (2.0)
Completeness (%) 99.9 (99.1) 98.2 (92.8)
Redundancy 7.2 (5.4) 3.9 (3.1)
Refinement
Resolution (A˚) 3.2 1.9
No. reflections/test set 66,876/3391 68,816/3482
Rwork / Rfree 19.9/24.3 19.1/23.1
No. atoms
Protein 20,042 6554
Solvent Not placed 869
B-factors
Protein 96.04 26.97
Solvent 34.54
Rmsd
Bond lengths (A˚) 0.010 0.007
Bond angles () 1.234 1.123
Ramachandran plot
(Procheck)
Favored and allowed
regions (%)
99.3 99.7
Disallowed regions (%) 0.7 0.3
Values in parentheses are for the highest resolution shell.
Structure
Structures of mAbs against the QNE of gp120currently available tools. The crystal structures of the uncom-
plexed form of the Fab fragments of PG16 and of the light chain
of PG9 have recently been described (Pancera et al., 2010; Pej-
chal et al., 2010), but no structural information about either the
QNE itself or how it interacts with these mAbs has been forth-
coming. Here, we describe the crystallization of the Fab frag-
ments of two QNE mAbs, human mAb 2909 and rhesus mAb
2.5B. Our structural analysis and computational modeling
suggest a structural model for the contours of QNE and a rational
hypothesis for how these QNEmAbs interact with their epitopes.
The results also have implications pertaining to the epitope
masking of V3 and CD4-induced conformational changes.
RESULTS
Structure Determination of Fab Fragments
of mAbs 2909 and 2.5B
The antigen binding fragments of mAbs 2909 (Fab 2909) and
2.5B (Fab 2.5B) were crystallized, and their structures deter-
mined and refined to resolutions of 3.2 and 1.9 A˚, respectively
(Table 1 and Figure 1). Fab 2909 crystallized in the trigonal space
group P3221 with six Fabs in the asymmetric unit (ASU), while
Fab 2.5B crystallized in themonoclinic space group P21 contain-
ing two Fabs in the ASU. The structure of Fab 2909, though at
a relatively low 3.2 A˚ resolution, has all residues of its comple-
mentarity determining regions (CDRs) accountable in the elec-
tron densities for all six Fabs in the ASU. On the other hand,
the 1.9 A˚ resolution structure of Fab 2.5B has six residues (aa
sequence EDDFGD) at the tip of its CDR H3 with poor electron
densities, indicating flexibility of the apex of its H3. The densities
of these six residues of one of the Fab (Fab1) were only traceable
at the 0.7 s level, while that for the other Fab (Fab2) were
completely missing; we have therefore left these residues out
for Fab2 in the final model. Noncrystallographic symmetry
(NCS) restraints were applied in the refinement of the low-reso-
lution 2909 structure, but three of the six Fabs in the crystal
have slightly better electron densities; nevertheless, all six
Fabs have essentially identical structures. We therefore, hence-
forth, refer to only one of the 2909 Fabs. Similarly, the two Fabs in
the 2.5B crystal are overall the same except for the side chains of
several key residues at, possibly, a part of the antigen-binding
site (see below). For clarity, we named these two Fabs Fab1
and Fab2 of 2.5B. Two Tyr residues (YH100a and YH100c; in the
Kabat numbering scheme (Kabat et al., 1991), and we use L
and H in the superscripts to refer residues in the light and heavy
chains, respectively) at the distal end of mAb 2909 CDR H3 were
shown recently to be sulfated (Changela et al., 2010), and we
were able to fit the sulfate group of these residues although three
of the six YH100c in the crystal did not have good side chain densi-
ties. We have shown here by mass spectrometry (see Figure S1
available online) that TyrH100i, located near the apex of its CDR
H3, of mAb 2.5B is also sulfated. However, we were not able
to place its sulfate group in the structure without generating
much negative density in the refinement. The structures of
Fabs 2909 and 2.5B are highly similar, and the RMSD of Ca
superimposition for the variable regions (Fv) is 0.71 A˚ (for
100% of the residues) for the light chains, and 1.40 A˚ (for 99%
of the residues) for the heavy chains; hence they superimpose
well with the exception of the distal ends of CDR H3 regions692 Structure 19, 691–699, May 11, 2011 ª2011 Elsevier Ltd All right(Figure 1E). The structural similarity may reflect their similar Ig
gene usages (Figure S1); both mAbs, though one is derived
from a human patient and the other from a rhesus monkey, use
the same VL3-21 for their light chains.
Structural Analysis of the Antigen Binding Sites
of Fabs 2909 and 2.5B
The presumed antigen binding sites of both mAbs 2909 and
2.5B, formed by the six CDRs of the light and heavy chains
(Figures 1C and 1D), have very unusual features, the most
striking of which is their long, extended CDR H3. The CDR H3
of Fab 2909 is 21 residues in length while that of 2.5B is 25 resi-
dues (Figure S1). CDR H3s of both Fabs 2909 and 2.5B form
a hairpin structure standing at the center of the CDR region
and extend away from the rest of the Fab with a distance greater
than 20 A˚ as measured from the apex Ca atom to its base. The
tips of all the CDR H3 loops of both Fabs 2909 and 2.5B have
some contacts with neighboring molecules in the crystal
packing; however, these contacts are minimal and vary from
molecule to molecule. For example, the only tip region of CDRs reserved
H1
H2
H3
L1
L2
L3
N
N
H1
H2
H3L1
L2
L3
N
N
VL VH
CL CH1
H3
VL VH
CL CH1
H3
A
B
C
D
E    
Figure 1. Crystal Structures of Fabs 2909
and 2.5B
(A) Ribbon representation of the structure of Fab
2909 in a side view with CDR H3 (red) pointing up.
The light chain and the rest of heavy chain are
colored cyan and green, respectively.
(B) Ribbon representation of the structure of Fab
2.5B.
(C) A top view of the CDRs of Fab 2909. The CDRs
are labeled and colored as magenta (L1), pink (L2),
violet (L3), yellow orange (H1), orange (H2), and
red (H3), respectively.
(D) A top view of the CDRs of Fab 2.5B.
(E) Superimposition of the variable domains of
Fabs 2909 (cyan and green) and 2.5B (blue and
dark green). Note that the two structures super-
imposed well except at the CDR H3 tips.
See also Figure S1.
Structure
Structures of mAbs against the QNE of gp120H3 of 2909 that make contacts with neighboring molecules are
the side chains of the sulfated YH100c and YH100a, located at
the very distal end of CDR H3. Their contact areas ranged
34–59 A˚2 for YH100c and 11–25 A˚2 for YH100a, respectively. The
largest of these values (59 and 25 A˚2) account for only 28%
and 12% of the available surface areas of these two particular
sulfated Tyr residues. Similarly, two of the tip residues, FH100f and
YH100i, of Fab1 of mAb 2.5B are involved in protein-protein
contacts with contact areas of 46 and 37 A˚2, again30% of their
available surface areas. Thus these contacts are likely to have
helped stabilize the CDR H3 loops in the crystal structures, but
unlikely to have affected the hairpin nature of these loops. CDR
H3s of bothmAbs 2909 and 2.5B contain five negatively charged
residues, and together with the negative charges of the other
CDR loops give the encompassing antigen binding sites anStructure 19, 691–699, May 11, 2011overall negative electrostatic surface.
This is similar to all the known structures
of human anti-V3 mAbs, whose nega-
tively charged antigen binding sites can
bind to the positively charged V3 crown
(Stanfield et al., 2004, 2006; Bell et al.,
2008; Burke et al., 2009; Jiang et al.,
2010). These two CDR H3s are also
populated with Tyr residues: CDR H3 of
mAb 2909 has six Tyr while that of mAb
2.5B has four; this, again, is similar to
two human anti-V3 mAbs 447-52D and
537-10D, both of which also have elon-
gated CDR H3s (Stanfield et al., 2004;
Burke et al., 2009). Five Tyr residues
(YH100k, YH100i, YH100g and the sulfated
YH100a and YH100c) of mAb 2909’s CDR
H3 line along the hairpin structure in
such a way so that their side chains
form a configuration of a circular
staircase.
As a first step in analyzing the antigen
binding sites of these two mAbs in order
to define their paratopes, the regions
that are most likely to be involved inprotein-protein contacts were identified using the Optimal Dock-
ing Area (ODA) function of ICM (Fernandez-Recio et al., 2005).
The ODA algorithm analyzes the physicochemical characteris-
tics of protein surfaces by computing desolvation energy upon
burial of various patches on the protein surface. Contributions
to desolvation from aromatic, aliphatic, polar and charged buried
atoms are optimized for best recognition of protein-protein
interaction sites. Probing spheres associated with the most
favorable desolvation score are predicted to indicate putative
protein interaction partner locations. This is a fast and accurate
method to predict regions of protein-protein interactions; in
a test study, this method was used and correctly located 80%
of the binding sites for general proteins and 100% for Abs (Fer-
nandez-Recio et al., 2005). As an additional test, we used ODA
analysis first with the structures of two anti-V3 mAbs, 447-52Dª2011 Elsevier Ltd All rights reserved 693
AB
Figure 2. ICMOptimal Docking Area Analyses of Fabs 2909 and 2.5B
ODA analysis of Fabs 2909 (A) and 2.5B (B). ODA uses desolvation energy to
accurately predict sites of protein-protein interaction, and spheres are placed
at the surface of the protein. The redness and size of the spheres are
proportional to the region’s likelihood to be involved in protein-protein inter-
actions. The results indicate that CDR H3 of both mAbs is predominantly
involved in binding their epitopes. See also Figure S2.
Structure
Structures of mAbs against the QNE of gp120and 537-10D, for which structures of antigen-antibody com-
plexes are available (Stanfield et al., 2004; Burke et al., 2009);
ODA accurately predicted the antigen binding sites (Figure S2).
Application of the ODA method to the Fab fragments of mAbs
2909 and 2.5B showed that the ‘‘hot spots’’ for protein-protein
interactions are almost exclusively concentrated on their CDR
H3s (Figure 2). Hence, the apexes of the CDR H3 regions in
both anti-QNEmAbs are likely to play central roles in these inter-
actions, and all sides of the CDR H3s are involved in interacting
with their epitopes. This property of the QNE mAbs contrasts694 Structure 19, 691–699, May 11, 2011 ª2011 Elsevier Ltd All rightwith that of the anti-V3 mAbs 447-52D and 537-10D, whose
antigen-binding sites are located only on one side of their long
CDR H3, sufficient for binding the relatively simpler epitope-V3
crown alone (Figure S2).
We further analyzed the antigen binding sites of the mAbs
2909 and 2.5B using a complementary method that determines
the existence of binding pockets in regions formed by the CDR
loops. For this, we used the PocketFinder function of ICM (An
et al., 2005). The PocketFinder algorithm uses protein surface
geometry as well as its van der Waals interaction potentials to
identify ligand-binding pockets. It was developed for small mole-
cules and had a 96.8% success rate when tested with 5616
binding sites collected from ligand-protein complexes, and
11,510 apo binding sites inferred from the complexes by
homology (An et al., 2005). Since this ICM function was originally
developed for small molecular ligands, we tested its ability first in
determining the antigen binding pockets on mAbs crystallized in
complex with their cognate peptide epitopes. The binding sites
for all eight human anti-V3 mAbs with known structures (Stan-
field et al., 2004, 2006; Bell et al., 2008; Burke et al., 2009; Jiang
et al., 2010) were correctly identified. We show for example, in
Figure 3D and Figure S3, the results for mAbs 447-52D and
537-10D.
Visual inspection shows that there are small pockets on the
surfaces of Fabs 2909 and 2.5B at surface areas formed by the
CDRs (not shown), but they are relatively shallow. We therefore
lowered the PocketFinder algorithm tolerance to 3.0 (which
gave reasonable results for anti-V3 mAbs) instead of using the
default value of 4.6. The PocketFinder function found two small
pockets (P1 and P2) at the antigen-binding site of Fab 2909
with volumes of 243 A˚3 (P1) and 127 A˚3 (P2) (inset, Figure 3A).
(In comparison, the 3D volumes for the antigen binding site
pockets of mAbs 447-52D and 537-10D are, at the 4.6 tolerance,
458 and 485 A˚3, respectively; Figure S3.) Both pockets of Fab
2909 are located at the base of CDR H3 with the first one formed
by residues from both light and heavy chains, while the second
pocket is formed by only heavy chain residues (Figures 3A and
3D). Drawing analogies from the structures of mAbs 447-52D
and 537-10D (Stanfield et al., 2004; Burke et al., 2009) (Figure 3D;
Figure S3), these pockets appear as sites of interaction with the
apexes of V3 and V2. The two Fabs in the 2.5B crystal gave
slightly different results (Figures 3B, 3C, and 3D), derived from
the different side chain conformations of several residues:
TrpL91, AspH58, TyrH100n, and HisH95a (Figures 3B and 3C, arrow-
heads).We term residues TrpL91, AspH58, and TyrH100n in 2.5B the
aromatic-acidic triad of the antigen binding site; it is also present
in Fab 2909 at the sameposition (Figure 3A, arrowheads). In Fab2
of 2.5B, the side chain of TrpL91 points down toward the interior of
the molecule (Figure 3C), while in Fab1, its side chain is flipped
upward and pushes away the side chain of HisH95a (Figure 3B).
Comparison of the pockets identified by ICM PocketFinder
showed that the residues forming these pockets are very similar
in position between Fabs 2909 and 2.5B (Figure 3).
Signatures of V3 Binding
The epitopes recognized by all QNE mAbs described to date
include the V3 region of gp120. Since the structures for a panel
of anti-V3 mAbs in complex with V3 peptides have been deter-
mined (Stanfield et al., 2004, 2006; Bell et al., 2008; Burkes reserved
AD
B C
Figure 3. Possible Antigen Binding Pockets of Fabs 2909 and 2.5B Identified by the PocketFinder Function of ICM
(A) Two pockets were found for the Fab 2909 antigen binding site (inset: surfaces illustrating pocket 1 (P1) and pocket 2 (P2) are colored blue and yellow,
respectively). The side chains of the residues lining the pockets are displayed and labeled, and they are colored the same as the pockets in the inset, except
TyrH100i which is involved in both pockets. Arrowheads point to three residues, TrpL91, AspH95a, and TyrH100k, that form the aromatic-acidic triad proposed to be
involved in binding the arch of V3 (see text).
(B) Two pockets are also identified for Fab1 of 2.5B. Again the side chains of residues lining the pockets are displayed. Only two of three residues forming the
aromatic-acidic triad (arrowheads), TrpL91 and TyrH100n are involved in lining P1. However, these two residues and the third residue, DH58 (light blue), together with
another light chain residue, HL95a (light blue) collectively made a conformational change between Fab1 and Fab2 (see Figure 3C).
(C) Two pockets of Fab2 of 2.5B. The aromatic-acidic triad (arrowheads) has slightly different conformation from that of Fab1.
(D) Potential paratope residues of Fabs 2009 and 2.5B identified by ICM PocketFinder. The top panel is a comparison of the actual paratope residues (yellow) of
mAbs 447-52D (PDB: 3GHB) and 537-10D (PDB: 3GHE) and that predicted by ICM PocketFinder (green). The predicted paratope residues for mAbs 2909 and
2.5B are indicated in the lower panel. CDR residues of light (L1-L3) and heavy (H1-H3) chains are numbered according to the Kabat definitions. Letter insertions
following a numeral (e.g., 27a, 27b, and 27c in CDR L1) are indicated by lowercase letters above the corresponding amino acids. See also Figure S3.
Structure
Structures of mAbs against the QNE of gp120et al., 2009; Jiang et al., 2010), we looked for elements in the
CDRs of Fabs 2909 and 2.5B that have characteristics similar
to those of anti-V3 mAbs. The structures of Fabs 2909 and
2.5B resemble those of mAbs 447-52D and 537-10D (Burke
et al., 2009), having rather extended structures of CDR H3s.
The Fabs of 2909 and 2.5B superimposed well with those of
447-52D and 537-10D, except that the CDR H3s have different
orientations (Figure S2C). The paratopes of both mAbs 447-52D
and 537-10D are of the so-called ‘‘ladle’’ type; i.e., their antigen
binding sites are shaped like a soup ladle with the CDR H3
forming the handle (Burke et al., 2009) and the N-terminal side
of the V3 crown interacting with the CDR H3 by main-chain inter-
actions, while the apex of the V3 crown falls into the bowl of
the ladle. The bowl of the antigenbinding site has a unique feature
allowing it to bind the GPGR archmotif of the V3 crown. In partic-
ular, both Fabs 447-52D and 537-10D have an aromatic-acidic
triad of Tyr-Trp-Asp/Glu (Figure S3) (Stanfield et al., 2004; Burke
et al., 2009). Inspection of the antigen binding sites of Fabs 2909
and 2.5B shows that both also have this aromatic-acidic group at
the base of the antigen-binding site (Figure 3). In the case of mAb
2.5B, the side chains of this triad adopted two conformations in
Fab1 and Fab2, suggesting that this region is somewhat flexible
and may allow an induced fit upon epitope binding.Structure 19,We then attempted to computationally dock V3 into the
antigen binding sites of Fabs 2909 and 2.5B, using a two-step
docking procedure in ICM: rigid-body docking followed by
side-chain optimization (Fernandez-Recio et al., 2002, 2004).
We first created a structure of V3 with SF162 sequence by
homology modeling based of a V3 structure in the context of
gp120 core (PDB: 2B4C). This full-length V3 was then docked
to the antigen binding sites of Fabs 2909 and 2.5B and the lowest
energy results are presented in Figure 4. The docked complexes
of both Fabs 2909 and 2.5B have very similar structural features:
the N-terminal side of the V3 crown forms main chain interac-
tions with the long CDR H3 with the GPGR arch of the crown
docked at CDR regions of those V3 binding signature residues.
DISCUSSION
Atomic structures of mAbs specific for HIV-1 gp120 QNE can
shed light on how they bind to their cognate epitopes. We
have determined the atomic structures of two QNE-specific
mAbs, one derived from B cells of an HIV-infected human and
the other from a SHIVSF162P4-infected rhesus macaque. Our
results show that both mAbs have long, extended CDR H3
regions with a straight beta hairpin structure and with shallow691–699, May 11, 2011 ª2011 Elsevier Ltd All rights reserved 695
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Figure 4. Computational Docking of V3 into
the Antigen Binding Sites of Fabs 2909 and
2.5B
A full-length V3 is docked into the antigen binding
sites of Fabs 2909 (A) and 2.5B (B) using a two-
step soft docking procedure of ICM (Fernandez-
Recio et al., 2002, 2004). The lowest energy
complexes are presented here and, for clarity, only
selected residues of V3 and the antigen binding
sites are shown. The light, heavy chains of the
mAbs and V3 are colored cyan, green and
magenta, respectively. The sulfated TyrH100i in Fab
2.5B (B) wasmodeled in the structure according to
the mass spectrometry data (Figure S1D). Note
the docked modes of both Fabs 2909 and 2.5B
are similar to each other and to that of V3 mAbs
447-52D and 537-10D (Figures S2A and S2B). See
also Figure S4.
Structure
Structures of mAbs against the QNE of gp120binding pockets formed by the base region of CDRH3 and other
CDRs (Figures 1–3). ICMODA analyses of the structures showed
that the CDR H3 regions of both mAbs display key protein-
protein interaction surfaces (Figure 2). Hence the CDR H3
portions of these mAbs appears to play a dominant role in
epitope binding. A complementary computational analysis of
the antigen binding sites formed by all six CDRs revealed
pockets at the base of the CDR H3 region which are likely to
be part of the paratopes of these two mAbs (Figure 3).
Comparison of the antigen binding sites of Fabs 2909 and
2.5B with that of anti-V3 human mAbs indicated that signatures
of V3 binding exist at their antigen binding sites. Computational
protein-protein docking allowed us to place a V3 into their
binding sites in a mode highly similar to that of anti-V3 mAbs
447-52D and 537-10D (Figure 4). However, due to the shallow-
ness of the pockets at their antigen binding sites, mAbs 2909
and 2.5B are not able to bind V3 alone. Our docking results,
together with the available gp120 structures derived from X-ray
crystallography and cryo-electron microscopy (Huang et al.,
2005, 2007; Liu et al., 2008), allowed us to further construct
a model of antigen-antibody interactions for 2909/2.5B (Fig-
ure S4A). This model, while highly speculative, provides several
clues of these interactions and suggests a way in configuring the
QNEs. First, this model suggests a spatial relationship between
the V1/V2 and V3 loops, and it explains how mAbs 2909 and
2.5B can interact simultaneously with both V2 and V3 loops:
one side of the CDR H3 binds to V3, the other side binds V2,
and the tips of the V2 and V3 loops reaches down into the
pockets at the base of CDRH3, agreeing with the ODA predicted
regions involved in the antigen-antibody interactions (Figure 2).
Second, this model indicates that the QNE occurs within a single
gp120 monomer; i.e., it consists of the V1/V2 and V3 loops from
a single molecule. This is in agreement with the proposed nature
of the epitope recognized by mAbs PG9 and PG16, and with the
finding that mAb PG9 can interact, albeit weakly, with gp120 of696 Structure 19, 691–699, May 11, 2011 ª2011 Elsevier Ltd All rights reservedstrain DU422 (Walker et al., 2009; Doores
and Burton, 2010). However, due to the
flexibility of the gp120 variable loops, it
appears that the stable QNE can only
form optimally in the gp120 trimeric spikeon the surface of virions and infected cells. Third, this model indi-
cates that the tip of the CDR H3s of mAbs 2909 and 2.5B can
reach the coreceptor binding site of gp120 and that this site
may be part of the QNE. This is where the N terminus of CCR5
interacts through sulfated Tyr residues (Huang et al., 2007),
and the Tyr residues at the apex of the CDR H3 of these mAbs
may serve the same purpose. This is supported by that fact
that Tyr residues at the apex of their CDR H3 are sulfated (Fig-
ure S1D) (Changela et al., 2010). Fourth, the spatial relationship
between V1/V2 and V3 in our model also suggests amechanistic
view for how V1/V2 might mask V3, and why exposure to CD4
enhances V3 exposure (Figure S4A). In the unbound or b12-
bound form, V1/V2 and V3 are located in spatial proximity and
may allow the former to mask the latter (Figure S4A). It is known
that, upon CD4 binding, the inner domain of gp120 undergoes
major conformational changes (Zhou et al., 2007; Liu et al.,
2008; White et al., 2010), V3 exposure is enhanced (Mbah
et al., 2001), and many HIV strains become more sensitive to
anti-V3 mAbs (Wu et al., 2008). This can be visualized as the
V1/V2 loop moves away from V3 upon binding to CD4 and the
bridging sheet forms as depicted in Figure S4 (Zhou et al.,
2007; Liu et al., 2008; White et al., 2010).
We also constructed a model for the antigen-antibody interac-
tion for the QNEmAb PG16 (Figure S4), whose Fab crystal struc-
ture was published recently (Pancera et al., 2010; Pejchal et al.,
2010). These structures showed that the long CDR H3 of PG16
does not form a straight beta hairpin like that of Fabs 2909 and
2.5B presented here. Instead, the CDR H3 apex of PG16 bends
sideways forming an additional secondary structure that was
termed a ‘‘hammerhead’’ (Pejchal et al., 2010), or an ‘‘axe’’ (Pan-
cera et al., 2010). If this configuration is a stable structure, as the
authors argue, and remains in the same configuration upon
epitope binding, the CDRH3 of PG16 will have a slightly different
way to approach the coreceptor binding site of gp120 (Supple-
mental Experimental Procedures and Figure S4B). However,
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Structures of mAbs against the QNE of gp120the configuration of the QNE for PG16 in our model is essentially
the same as that of 2909/2.5B (Figures S4A and S4B). This is
supported by recent data that that a K160N mutation in V2 is
primarily responsible for limiting the neutralization breadth of
mAb 2909, while a reverse mutation will substantially reduce
the breadth of PG16 (Wu et al., 2011).
The fact that the only mAbs that have been selected to date
using neutralization assays are QNE-specific and that these
mAbs are all extremely potent and target overlapping epitopes
suggests that Abs of this type may be highly desirable to induce
with a prophylactic vaccine. It is not yet clear, however, whether
these mAbs are rare or commonly made by infected humans
(Walker et al., 2010). If they can be found only rarely, it would
suggest that virions and native gp120 are not ideal immunogens
for the induction of highly potent anti-QNE Abs; moreover,
a trimeric gp140-based vaccine would need to assume the
correct conformation to allow formation of the QNE, a feat that
has yet to be achieved. The weak reactivity of PG9 with mono-
meric gp120 and trimerized gp140 constructs, and the absence
of reactivity with these ligands by PG16 (Walker et al., 2009), indi-
cates that such immunogens need further refinement if they are
to be used to induce QNE Abs. A modified monomeric gp120
that stabilizes the V2/V3 spatial relationship, as suggested by
our model (Figure S4), or an engineered protein that presents
a structural mimotope of the QNE may be better suited to elicit
these types of neutralizing Abs. The structural data and models
presented here may serve as a first step in the design of such
immunogens.EXPERIMENTAL PROCEDURES
Monoclonal Antibodies
Monoclonal Ab 2909 was developed from the cells of an individual chronically
infected with clade B HIV-1, using a previously described cellular method
(Gorny et al., 2005). Monoclonal Ab 2909 belongs to the IgG1 subclass and
bears lambda light chains. Monoclonal Ab 2.5B was generated using a cellular
method from a rhesus macaque 7 months postinfection with SHIVSF162P4
(Robinson et al., 2010). This mAb is also an IgG1 with lambda light chains.
The variable domains of the heavy and light chains of both mAbs were
sequenced as previously described (Jeffs et al., 2001; Gorny et al., 2009)
and the sequences were analyzed using the International ImMunoGeneTics
(IMGT) information system (http://imgt.cines.fr). The immunoglobulin (Ig)
gene usage by the mAbs is shown in Figure S1. Identification of tyrosine
sulfation of TyrH100i in CDR H3 of 2.5B was performed by MS Bioworks LLC
(Ann Arbor,MI). A gel band of Fab 2.5B heavy chain was digested with elastase
at 37C for 18 hr and quenchedwith formic acid; the supernatant was analyzed
by MS/MS mass spectrometry directly without further processing.
Crystallization and Structure Determination
Fabs of mAbs 2909 and 2.5B were generated by papain digestion and purified
using size exclusion chromatography (Burke et al., 2009). The purified Fabs in
20 mM Tris (pH 6.5), and 100 mM NaCl were concentrated for crystallization.
Fab 2909 was crystallized by the microbatch method under paraffin oil with
0.5 ml Fab at 30 mg/ml mixed with an equal amount of buffer containing
14% PEG 8000, 0.1M HEPES (pH 6.8), 0.1M glycine, and 8% ethylene glycol.
Fab 2.5B was crystallized by the vapor diffusion hanging drop method with
0.5 ml of Fab at 20 mg/ml mixed with an equal volume of well solution contain-
ing 18% PEG 3350 and 100 mM ammonium nitrate (pH 6.3).
Several synchrotron beamlines were used for characterization of the crys-
tals and diffraction data collection, including X4C and X6A at the National
Synchrotron Light Source (NSLS) and IMCA-CAT, and GM/CA-CAT at the
Advanced Photo Source (APS). The final data sets for both Fabs were
collected at GM/CA-CAT. The structures were determined by molecularStructure 19,replacement using MOLREP in the CCP4 software package with a starting
models built using ICM (Abagyan et al., 1994) on a structure of the homologous
Fab-Hyb3 (Hulsmeyer et al., 2005) (PDB: 1W72), and refined by cycles of
manual adjustments and computational minimizations using Coot (Emsley
and Cowtan, 2004), O (Jones, 2004), CNS (Brunger et al., 1998), Refmac
(Murshudov et al., 1997), and Phenix (version 1.6.4) (Adams et al., 2002).
NCS restraints were applied by Phenix in the refinement of the 3.2 A˚ resolution
structure of Fab 2909. Due the elbow angle differences (up to 15; not shown)
of the six Fabs in the asymmetric unit, the restraints were applied separately for
the variable and constant regions of each chain. However, the restraints were
not imposed on the side chains of CDR H3 due to the different packing envi-
ronments of the tip residues. Rfree was calculated for both structures with
5% of randomly selected reflections, which distributed about equally in all
resolution shells (not shown). Structural analysis and modeling were
carried out using ICM and the figures were created using ICM and Pymol
(DeLano, 2002).
Computational Analysis of the Antigen Binding Sites (Paratopes)
of Fabs 2909 and 2.5B
The ICM Optical Docking Area (ODA) function was used to identify regions of
the Fabs likely involved in antigen-antibody interactions of Fabs 2909 and
2.5B. The algorithm identifies surface patches with optimal docking desolva-
tion energy based on atomic solvation parameters adjusted for protein-protein
interactions (Fernandez-Recio et al., 2005). It has been benchmarked on
a panel of nonhomologous proteins involved in nonobligate protein-protein
interactions. The ICM PocketFinder function was used to identify the potential
binding pockets on the surfaces of Fabs 2909 and 2.5B. The algorithm builds
a grid map of the van der Waals potential, and the position and size of the
antigen binding pocket(s) are determined based on the construction of equipo-
tential surfaces after a smoothing transformation of the map that emphasizes
buried continuous regions of low potential (An et al., 2005). A tolerance param-
eter of 3.0 was used for mAbs 2909 and 2.5B instead of the default value,
which is 4.6; a lower value results in a greater sensitivity.
A two-step soft protein-protein docking procedure of ICMwas used to auto-
matically dock the V3 model into the antigen binding sites of Fabs 2909 and
2.5B (Fernandez-Recio et al., 2002, 2004). The V3 model was first docked
as a rigid body to the antigen binding sites. Then, a modified Monte-Carlo
docking procedure was used to refine the docking position and conformation
of the V3 model as well as the interacting residues of the Fabs, allowing for
marginal flexibility in the backbone torsion angle and full side chain flexibility.
Each iteration of the Monte-Carlo procedure was followed by a pseudo-Brow-
nianmovement of the V3 position and a local energyminimization. The iterative
process was repeated several million times until a minimum energy was
converged upon.
ACCESSION NUMBERS
The atomic coordinates of both structures have been deposited in RCSB
Protein Data Bank with PDB IDs 3Q6F for Fab 2909 and 3Q6G for Fab 2.5B.
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and four figures and can be found with this article online at doi:10.1016/j.str.
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